CSIMarket Company Name, Ticker, Suppliers, else..
 
Crinetics Pharmaceuticals Inc   (NASDAQ: CRNX)
 
Price: $84.9500 $84.95 %
Day's High: $84.94999694824219 Week Perf: 0.12 %
Day's Low: $ 84.95 30 Day Perf: 1.3 %
Volume (M): 0 52 Wk High: $ 87.50
Volume (M$): $ 0 52 Wk Avg: $49.16
Open: $84.95 52 Wk Low: $32.30



 Market Capitalization (Millions $) 8,967
 Shares Outstanding (Millions) 106
 Employees 594
 Revenues (TTM) (Millions $) 42
 Net Income (TTM) (Millions $) -502
 Cash Flow (TTM) (Millions $) 60
 Capital Exp. (TTM) (Millions $) 3

Business Description


Crinetics Pharmaceuticals Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics for rare endocrine disorders and endocrine-related cancers. The company's research and development efforts aim to address significant unmet medical needs and improve the quality of life for patients. Crinetics' pipeline includes potential treatments for diseases such as acromegaly, neuroendocrine tumors, and congenital hyperinsulinism. By leveraging its expertise in peptide chemistry and small molecule drug design, Crinetics Pharmaceuticals strives to bring innovative therapies to patients worldwide.


   Company Address: 6055 Lusk Boulevard San Diego 92121 CA
   Company Phone Number: 450-6464   Stock Exchange / Ticker: NASDAQ CRNX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ACAD   -2.97%    
MIRM   -5.66%    
MNKD   -14.42%    
PBYI   -1.49%    
TEVA        6.77% 
VTRS        0.24% 
• View Complete Report
   



Shares

Crinetics Pharmaceuticals Strengthens Talent Acquisition with Strategic Inducement Grants

Published Thu, Apr 10 2025 9:04 PM UTC

In a decisive move aimed at bolstering its workforce and attracting top-tier talent, Crinetics Pharmaceuticals, a leading player in the biopharmaceutical industry, announced on April 10, 2025, that its Compensation Committee has granted significant stock options and restricted stock unit (RSU) awards to a select group of new nonexecutive employees. This initiative comes unde...
Shares

Crinetics Pharmaceuticals Strengthens Talent Acquisition Strategy with Significant Stock Option Grants,

Published Fri, Jan 10 2025 10:15 PM UTC

Crinetics Pharmaceuticals Announces Inducement Grants to New Employees Amid Growth StrategyOn January 10, 2025, Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a biotechnology firm focused on developing therapies for endocrine diseases, made a significant announcement regarding its employee incentive strategy. The company disclosed that its Compensation Committee had granted...
Shares

Crinetics Pharmaceuticals Enhances Workforce Competitiveness with Nasdaq-Compliant Inducement Grants,

Published Mon, Feb 10 2025 9:45 PM UTC

In a significant move to bolster its workforce, Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) has announced the issuance of inducement grants to 14 new non-executive employees, a decision that strategically aligns with Nasdaq Listing Rule 5635(c)(4). This development was made public in a press release on February 10, 2025, and highlights the company s commitment to attracti...
Shares

Crinetics Pharmaceuticals Boosts Workforce with Stock Options Amid Breakthroughs in Cancer Treatment,

Published Wed, Dec 11 2024 1:44 AM UTC

Crinetics Pharmaceuticals Awards Stock Options to New Non-Executive Employees Amid Promising Developments in Neuroendocrine Tumor TreatmentOn December 10, 2024, Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced significant inducement grants for sixteen new non-executive employees, issuing non-qualified stock option awards for a total of 146,400 shares of its common st...
Clinical Study

Crinetics Pharmaceuticals to Unveil Promising Neuroendocrine Tumor Candidates at NANETS Annual Meeting

Published Thu, Nov 14 2024 9:05 PM UTC

UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting Crinetics Pharmaceuticals, a leading innovator in the development of novel therapeutics for endocrine diseases and cancers, is set to debut significant advancements from its pipeline at the 2023 No...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 212.72
Price to Sales (Expected) -
Price to Book 7.52
PEG (TTM) -

Financial Strength Current
Quick Ratio 29.41
Working Capital Ratio 30.13
Leverage Ratio (MRQ) 0.11
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -5.06 $
Revenues (TTM) 0.4 $
Cash Flow (TTM) 0.57 $
Cash 22.26 $
Book Value 11.29 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 70,970
Net Income per Employee (TTM) -844,455
Receivable Turnover Ratio (TTM) 9.25
Inventory Turnover Ratio (TTM) 0.67
Asset Turnover Ratio (TTM) 0.03

Profitability Ratios Current
Gross Margin (MRQ) 99.39 %
Operating Margin (MRQ) -527.35 %
Net Margin (MRQ) -481.15 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Crinetics Pharmaceuticals Inc's Segments
Product    136.73 % of total Revenue
License and Service    6 % of total Revenue
Reportable    142.73 % of total Revenue

  Crinetics Pharmaceuticals Inc Outlook

On February 28 2024 the Crinetics Pharmaceuticals Inc provided following guidance

Crinetics Pharmaceuticals Inc. released their financial results for the fourth quarter and full year of 2023 along with a corporate update. The company is eagerly awaiting the topline results of their Phase 3 PATHFNDR-2 study, which are expected to be released in March 2024. These results will determine the next steps for the company, including the submission of a New Drug Application (NDA) for a potential treatment for Acromegaly, which is anticipated in the second half of 2024.

The company is optimistic about the potential of their new treatment and is looking forward to the results of the upcoming study. They are committed to advancing their research and development efforts in order to bring innova...





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.